Switch theme
Sign up to access all valuation multiples
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.
2010
228
LTM Revenue $180M
LTM EBITDA -$103M
$278M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Coherus BioSciences has a last 12-month revenue (LTM) of $180M and a last 12-month EBITDA of -$103M.
In the most recent fiscal year, Coherus BioSciences achieved revenue of $267M and an EBITDA of $60.9M.
Coherus BioSciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Coherus BioSciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $180M | XXX | $267M | XXX | XXX | XXX |
| Gross Profit | $107M | XXX | $149M | XXX | XXX | XXX |
| Gross Margin | 59% | XXX | 56% | XXX | XXX | XXX |
| EBITDA | -$103M | XXX | $60.9M | XXX | XXX | XXX |
| EBITDA Margin | -57% | XXX | 23% | XXX | XXX | XXX |
| EBIT | -$125M | XXX | -$112M | XXX | XXX | XXX |
| EBIT Margin | -70% | XXX | -42% | XXX | XXX | XXX |
| Net Profit | -$44.0M | XXX | $28.5M | XXX | XXX | XXX |
| Net Margin | -24% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $139M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Coherus BioSciences's stock price is $1.
Coherus BioSciences has current market cap of $90.3M, and EV of $278M.
See Coherus BioSciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $278M | $90.3M | XXX | XXX | XXX | XXX | $-0.40 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Coherus BioSciences has market cap of $90.3M and EV of $278M.
Coherus BioSciences's trades at 1.0x EV/Revenue multiple, and 4.6x EV/EBITDA.
Equity research analysts estimate Coherus BioSciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Coherus BioSciences has a P/E ratio of -2.1x.
See valuation multiples for Coherus BioSciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $90.3M | XXX | $90.3M | XXX | XXX | XXX |
| EV (current) | $278M | XXX | $278M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | -2.7x | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBIT | -2.2x | XXX | -2.5x | XXX | XXX | XXX |
| EV/Gross Profit | 2.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.1x | XXX | 3.2x | XXX | XXX | XXX |
| EV/FCF | -6.3x | XXX | -13.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCoherus BioSciences's last 12 month revenue growth is -59%
Coherus BioSciences's revenue per employee in the last FY averaged $1.2M, while opex per employee averaged $1.1M for the same period.
Coherus BioSciences's rule of 40 is -134% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Coherus BioSciences's rule of X is -204% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Coherus BioSciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -59% | XXX | -39% | XXX | XXX | XXX |
| EBITDA Margin | -57% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -134% | XXX | -36% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -204% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 98% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Coherus BioSciences acquired XXX companies to date.
Last acquisition by Coherus BioSciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Coherus BioSciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Coherus BioSciences founded? | Coherus BioSciences was founded in 2010. |
| Where is Coherus BioSciences headquartered? | Coherus BioSciences is headquartered in United States of America. |
| How many employees does Coherus BioSciences have? | As of today, Coherus BioSciences has 228 employees. |
| Who is the CEO of Coherus BioSciences? | Coherus BioSciences's CEO is Mr. Dennis M. Lanfear. |
| Is Coherus BioSciences publicy listed? | Yes, Coherus BioSciences is a public company listed on NAS. |
| What is the stock symbol of Coherus BioSciences? | Coherus BioSciences trades under CHRS ticker. |
| When did Coherus BioSciences go public? | Coherus BioSciences went public in 2014. |
| Who are competitors of Coherus BioSciences? | Similar companies to Coherus BioSciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Coherus BioSciences? | Coherus BioSciences's current market cap is $90.3M |
| What is the current revenue of Coherus BioSciences? | Coherus BioSciences's last 12 months revenue is $180M. |
| What is the current revenue growth of Coherus BioSciences? | Coherus BioSciences revenue growth (NTM/LTM) is -59%. |
| What is the current EV/Revenue multiple of Coherus BioSciences? | Current revenue multiple of Coherus BioSciences is 1.5x. |
| Is Coherus BioSciences profitable? | Yes, Coherus BioSciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Coherus BioSciences? | Coherus BioSciences's last 12 months EBITDA is -$103M. |
| What is Coherus BioSciences's EBITDA margin? | Coherus BioSciences's last 12 months EBITDA margin is -57%. |
| What is the current EV/EBITDA multiple of Coherus BioSciences? | Current EBITDA multiple of Coherus BioSciences is -2.7x. |
| What is the current FCF of Coherus BioSciences? | Coherus BioSciences's last 12 months FCF is -$43.9M. |
| What is Coherus BioSciences's FCF margin? | Coherus BioSciences's last 12 months FCF margin is -24%. |
| What is the current EV/FCF multiple of Coherus BioSciences? | Current FCF multiple of Coherus BioSciences is -6.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
